Syndax Pharmaceuticals, Inc., was founded in 2005 to extend and improve the lives of cancer patients by developing and commercializing novel therapies. Our vision is bold—to modify the tumor phenotype, allowing for new therapeutic opportunities that restore or extend the benefit of targeted therapies. Our vision is practical—to develop effective regimens that have broad commercial potential by optimizing features important to patients, physicians, and payers.